Targeting the IRF-1 signaling pathway may offer a novel therapeutic strategy for MS by protecting oligodendrocytes and myelin, thereby reducing axonal injury and achieving neuroprotection [92]. The gene discussed is IRF1; the disease is myeloid sarcoma.